July 18 (Reuters) - U. drugmaker Pfizer and venture capital firm Flagship Pioneering on Tuesday agreed to invest $100 million to discover and develop 10 new potential drugs targeting diseases with few or no treatment options. Pfizer, which would gain access to Pioneering's research platform and pre-clinical study resources, would provide funding for the development of each of the selected drugs and have an option to acquire them